000597.SZ
东北制药
SZSE · Healthcare · C 制造业 · CN
CNY 4.88
−2.59%Sep 1, 2026, 14:22 UTC
On September 1, 2026, after market close, 12 A-share listed companies including Yiatong, Henggong Precision, Weihong, Jiuzhou Yigui, Zhongman Petroleum, Shanghai Xiba, Gongdong Medical, Jincang Group, Northeast Pharmaceutical, Kingmed Diagnostics, Yongzhen, and Fuchun Dyeing disclosed plans to reduce holdings, while Huaxia Eye Hospital disclosed a plan to increase holdings.
Source:Sep 1, 2026, 09:14 UTC
Northeast Pharmaceutical director Guo Jianmin plans to sell up to 0.0560% of the company's shares within three months starting 15 trading days after September 2, 2026.
Source:Jul 22, 2026, 11:54 UTC
Northeast Pharmaceutical received approval from the National Medical Products Administration for its marketing application of the chemical active pharmaceutical ingredient baloxavir marboxil, valid until July 19, 2031.
Source:Jul 12, 2026, 08:23 UTC
Northeast Pharmaceutical's subsidiaries have 14 drug specifications included in the 2026 edition of the National Essential Drug List.
Source: